Report Overview

The Australia Parkinsons Disease Drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Parkinsons disease is a progressive, degenerative neurological condition that affects a persons control of their body movements. It is not contagious or fatal that is, a person cannot die from Parkinsons symptoms. It is thought that the disease may be genetic in a very small percentage of cases. Parkinsons disease is classified as a progressive neurological condition. Symptoms of the disease are caused by the progressive degeneration of nerve cells in the middle area of the brain. This causes a lack of dopamine, a chemical messenger (neurotransmitter) necessary for smooth, controlled movements. The symptoms appear when about 70% of the dopamine-producing cells have stopped working normally.

It is estimated that approximately four people per 1,000 in Australia have Parkinsons disease, with the incidence increasing to one in 100 over the age of 60. In Australia, approximately 80,000 people are living with Parkinsons disease, with one in five of these people being diagnosed before the age of 50.



Market Drivers

Parkinsons disease Treatment Market is mainly driven by the growing prevalence of Parkinsons disease and government funding for research on Parkinsons disease. The increase in the number of geriatric population and technological advancements such as combination therapies for prolonging the action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes that are possible to boost the Parkinsons disease Treatment market. Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD). Recently, there have been some major product launches in Parkinson's disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals amantadine extended-release capsules, Gocovri, were launched in January 2018. Gocovri was the first drug indicated for dyskinesia developed due to the long-term use of levodopa.